{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:37:08Z","timestamp":1793266628394,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.105022","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:48:30Z","timestamp":1787928510000},"page":"105022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4007-6670","authenticated-orcid":false,"given":"Ana Carolina","family":"Covre Coan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-2453","authenticated-orcid":false,"given":"Rodolfo A.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-4999","authenticated-orcid":false,"given":"Carlos Vergara","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonzo Armani","family":"Prata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1900-9432","authenticated-orcid":false,"given":"Christian Ken","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Talavera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-3287","authenticated-orcid":false,"given":"Michael","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpet.2026.105022_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease","volume":"118","author":"Budoff","year":"2016","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jpet.2026.105022_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"19","key":"10.1016\/j.jpet.2026.105022_bib4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jpet.2026.105022_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2026.105022_bib6","article-title":"CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk","volume":"8","author":"Marston","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2026.105022_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156187","article-title":"Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials","volume":"167","author":"De Moura De Souza","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00210-025-04406-2","article-title":"Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients","volume":"399","author":"Serag","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.105022_bib9","first-page":"e574","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk\u2014a systematic review and meta-analysis","volume":"32","author":"Raja","year":"2025","journal-title":"Am J Ther"},{"issue":"8","key":"10.1016\/j.jpet.2026.105022_bib10","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1097\/MS9.0000000000003505","article-title":"The impact of olezarsen on hypertriglyceridemia in high cardiovascular risk patients: a systematic review, meta-analysis, and meta-regression","volume":"87","author":"Ashraf","year":"2025","journal-title":"Ann Med Surg"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12944-024-02389-2","article-title":"Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia: a network meta-analysis of randomized controlled trials","volume":"24","author":"Mahmoud","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jpet.2026.105022_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas","volume":"46","author":"Page","year":"2022","journal-title":"Rev Panam Salud Publica Pan Am J Public Health"},{"key":"10.1016\/j.jpet.2026.105022_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jpet.2026.105022_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jpet.2026.105022_bib15","series-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","author":"Spiegelhalter","year":"2003"},{"issue":"6","key":"10.1016\/j.jpet.2026.105022_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R Package","volume":"93","author":"R\u00f6ver","year":"2020","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jpet.2026.105022_bib17","series-title":"Statistical Rethinking: A Bayesian Course With Examples in R and Stan","first-page":"1","author":"McElreath","year":"2020"},{"issue":"2","key":"10.1016\/j.jpet.2026.105022_bib18","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ijcard.2013.06.040","article-title":"Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia","volume":"170","author":"Pirillo","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.jpet.2026.105022_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jpet.2026.105022_bib21","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jpet.2026.105022_bib22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jpet.2026.105022_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","article-title":"Apolipoproteins in vascular biology and atherosclerotic disease","volume":"19","author":"Mehta","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jpet.2026.105022_bib24","series-title":"Bayesian Methods in Pharmaceutical Research","year":"2020"},{"issue":"14","key":"10.1016\/j.jpet.2026.105022_bib25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.jpet.2026.105022_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jpet.2026.105022_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jpet.2026.105022_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jpet.2026.105022_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-9343(87)90873-4","article-title":"Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives","volume":"83","author":"Ginsberg","year":"1987","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.105022_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","article-title":"Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome","volume":"52","author":"Watts","year":"2003","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.jpet.2026.105022_bib31","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jpet.2026.105022_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.jpet.2026.105022_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jpet.2026.105022_bib34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.105022_bib35","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.jpet.2026.105022_bib37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","article-title":"Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells","volume":"114","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jpet.2026.105022_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bbrc.2015.04.147","article-title":"Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis","volume":"462","author":"Han","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jpet.2026.105022_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jpet.2026.105022_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5551\/jat.E607","article-title":"Apolipoprotein CIII links dyslipidemia with atherosclerosis","volume":"16","author":"Kawakami","year":"2009","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"10.1016\/j.jpet.2026.105022_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98045","article-title":"Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk","volume":"3","author":"Morton","year":"2018","journal-title":"JCI Insight"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:17:56Z","timestamp":1793265476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652601222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S002235652601222X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105022","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105022"}}